Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Capricor Therapeutics stock
Learn how to easily invest in Capricor Therapeutics stock.
Capricor Therapeutics is a biotechnology business based in the US. Capricor Therapeutics shares (CAPR) are listed on the NASDAQ and all prices are listed in US Dollars. Capricor Therapeutics employs 48 staff and has a trailing 12-month revenue of around $1.6 million.
How to buy Capricor Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – CAPR. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Capricor Therapeutics stock price (NASDAQ: CAPR)Use our graph to track the performance of CAPR stocks over time.
Capricor Therapeutics shares at a glance
|Latest market close||$4.24|
|52-week range||$2.81 - $6.58|
|50-day moving average||$4.03|
|200-day moving average||$4.47|
|Wall St. target price||$15.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.96|
Buy Capricor Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Capricor Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Capricor Therapeutics price performance over time
|1 week (2023-01-20)||-2.53%|
|1 month (2022-12-28)||21.14%|
|3 months (2022-10-28)||-24.15%|
|6 months (2022-07-28)||-6.19%|
|1 year (2022-01-28)||34.60%|
|2 years (2021-01-28)||-33.54%|
|3 years (2020-01-28)||161.73%|
|5 years (2018-01-26)||102.87%|
Capricor Therapeutics financials
|Revenue TTM||$1.6 million|
|Gross profit TTM||$-13,326,147|
|Return on assets TTM||-36.09%|
|Return on equity TTM||-105.4%|
|Market capitalisation||$115.1 million|
TTM: trailing 12 months
Capricor Therapeutics share dividends
We're not expecting Capricor Therapeutics to pay a dividend over the next 12 months.
Have Capricor Therapeutics's shares ever split?
Capricor Therapeutics's shares were split on a 1:10 basis on 4 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Capricor Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Capricor Therapeutics shares which in turn could have impacted Capricor Therapeutics's share price.
Capricor Therapeutics share price volatility
Over the last 12 months, Capricor Therapeutics's shares have ranged in value from as little as $2.81 up to $6.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Capricor Therapeutics's is 4.1737. This would suggest that Capricor Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Capricor Therapeutics overview
Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Capricor Therapeutics in the news
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
Frequently asked questionsWhat percentage of Capricor Therapeutics is owned by insiders or institutions?
Currently 2.645% of Capricor Therapeutics shares are held by insiders and 11.138% by institutions. How many people work for Capricor Therapeutics?
Latest data suggests 48 work at Capricor Therapeutics. When does the fiscal year end for Capricor Therapeutics?
Capricor Therapeutics's fiscal year ends in December. Where is Capricor Therapeutics based?
Capricor Therapeutics's address is: 10865 Road to the Cure, San Diego, CA, United States, 92121 What is Capricor Therapeutics's ISIN number?
Capricor Therapeutics's international securities identification number is: US14070B3096 What is Capricor Therapeutics's CUSIP number?
Capricor Therapeutics's Committee on Uniform Securities Identification Procedures number is: 14070B309
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert